Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
top-n44
- Development stage
- Preclinical
- Lead developer
- Topadur Pharma
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
TOP-N44 is a novel hybrid small molecule drug developed by Topadur Pharma for topical use, primarily targeting the prevention of skin fibrosis and scarring, including hypertrophic scars and keloids. Its mechanism of action involves suppressing inflammation and inhibiting fibroblast activation to prevent excessive scar formation. Preclinical data indicate that it inhibits uncontrolled scarring in human skin fibroblasts. Mechanistically, it acts as a peptide hydrolase inhibitor and has immunosuppressant properties. The drug is being investigated for indications such as burns, cicatrix (scars), and systemic scleroderma[1][2][3].
- Other names
- TOP-N44TOP-N-44TOP-N 44TOP N44
Beyond the preview
Go deeper on top-n44.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on top-n44.